Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Warnings: Allergic Reactions: Do not use in patients with known vitamin B12 hypersensitivity
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently without UK marketing authorisation from the MHRA or EMA
Studies document enhanced angiogenesis with increased blood vessel formation in wound beds, providing better oxygen and nutrient delivery to healing tissues
Each benefit below offers insight into how this innovative treatment, administered by ProCare Wellness Institute, can improve your health and well-being
Do It Yourself Options We carry Daily Synergistics Superfood Complete Shake in the office
BPC-157 is also named on WADA's Prohibited List under section S0 (Non-Approved Substances), the first time WADA named a specific substance by name as an example within that category (added for the 2022 List)
